Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fewer Than Half Of Children On Medicaid Receive Life-Saving Sickle-Cell Screenings, CDC Says

Executive Summary

A CDC study found that fewer than half of children with sickle cell disease were getting screened for strokes, and fewer than 40% of children were taking recommended medications.  

You may also be interested in...



Start-Up Spotlight: NovaSignal Aims To Commercialize Transcranial Ultrasound

With a mostly forgotten imaging modality, NovaSignal is trying to create the “fifth vital sign.” Medtech Insight spoke to chairman and chief executive officer, Diane Bryant, to learn more about the company's transcranial ultrasound technology.

Stroke Devices: Hope Amid Headwinds

Despite market headwinds, the endovascular treatment of acute ischemic stroke remains a growing and highly under-penetrated market opportunity valued at more than $1 billion worldwide. Although advances in neurothrombectomy devices, access catheters, imaging, and neuroprotective therapies have the potential to help expand the treatable population, positive Level I clinical evidence is needed to drive adoption and market growth.

CDS Final Guidance Draws More Criticism, This Time From Congress

Senator Bill Cassidy says FDA “disregarded” Congressional intent by expanding its authority to regulate clinical decision support software.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel